Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 3, 1996, Pages 617-622

  Feldmesser, Marta ^a   Mukherjee, Jean ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCYTOSINE; MANNAN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL MEMBRANE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG EFFECT; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MACROPHAGE; MOUSE; NONHUMAN;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; FLUCYTOSINE; IMMUNOGLOBULIN G; MACROPHAGES; MICE; MICE, INBRED A; MICROBIAL SENSITIVITY TESTS; PHAGOCYTOSIS; POLYSACCHARIDES;

EID: 0029932396     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.3.617     Document Type: Article

References (10)

1. Block, E. R. & Bennett, J. E. (1973). The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis. Proceedings of the Society of Experimental Biology and Medicine 142, 476-80.
2. Casadevall, A., Mukherjee, J., Devi, S. J. N., Schneerson, R., Robbins, J. B. & Scharff, M. D. (1992). Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxid conjugate vaccine have the same specificity as those elicited in infection. Journal of Infectious Diseases 65, 1086-93.
3. Devi, S. J. N., Schneerson, R., Egan, W., Ulrich, T. J., Bryla, D., Robbins, J. B. et al. (1991). Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infection and Immunity 59, 3700-7.
4. Dromer, F. & Charreire, J. (1991). Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. Journal of Infectious Diseases 163, 1114-20.
5. Francis, P. & Walsh, T. J. (1992). Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clinical Infectious Diseases 15, 741-5.
6. Larsen, R. A., Bozette, S. A., Jones, B. E., Haghighat, D., Leal, M. A., Forthal, D. et al. (1994). Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases 19, 741-5.
7. Levitz, S. M., DiBenedetto, D. J. & Diamond, R. D. (1987). A rapid fluorescent assay to distinguish attached from phagocytized yeast particles. Journal of Immunologial Methods 101, 37-42.
8. Mukherjee, J., Zuckier, L., ScharfF, M. D. & Casadevall, A. (1994). Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with Amphotericin B. Antimicrobial Agents and Chemotherapy 38, 580-7.
9. Mukherjee, S., Lee, S., Mukherjee, J., Scharff, M. D. & Casadevall, A. (1994). Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infection and Immunity 62, 1079-88.
10. Ralph, P., Prichard, J. & Cohn, M. (1975). Reticulum cell sarcoma: an effector cell in antibody-dependent cell-mediated immunity. Journal of Immunology 114, 898-905.